Ivonescimab Shows 26% Reduction in Death Risk for EGFR-Mutated NSCLC Patients in Phase 3 Trial

November 7, 2025

Karuna Therapeutics Phase 1b Trial Results Reinforce Cardiovascular Safety of Schizophrenia Treatment KarXT

November 22, 2023

AbbVie Licenses Ex-China Rights to RemeGen’s PD-1/VEGF Bispecific RC148 for $650 Million Upfront

January 14, 2026

Must Read

Evommune Reports Phase 2a EVO301 Data in Moderate to Severe Atopic Dermatitis

February 12, 2026

FDA Rejects REGENXBIO’s RGX-121 Gene Therapy for Hunter Syndrome, Requests New Study

February 12, 2026

Eli Lilly Discontinues Three Clinical-Stage Programs Including Prevail Gene Therapy

February 12, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Merck Gets $700M Funding From Blackstone For Cancer Therapy R&D

Pfizer to Withdraw Vyndaqel in the U.S. Before Patent Expiration in 2028

Roche Ends Development of Obesity Candidate CT-173 and Discontinues Multiple Early-Stage Programs

$20 Million Pediatric CRISPR Center Launched to Develop Treatments for Rare Genetic Diseases

Evommune Reports Phase 2a EVO301 Data in Moderate to Severe Atopic Dermatitis

Eli Lilly Discontinues Three Clinical-Stage Programs Including Prevail Gene Therapy

CagriSema Shows Greater Blood Sugar and Weight Reduction Than Semaglutide in Phase 3 Trial

Sanofi Reports Divergent Phase III Results for Venglustat in Gaucher and Fabry Diseases

Lilly Acquires Orna to Enter In Vivo CAR-T Development for Autoimmune Diseases

Iambic and Takeda Enter Multiyear AI Drug Discovery Partnership Valued at Over $1.7 Billion

AstraZeneca commits $15 billion investment in China to advance radioconjugates and cell therapy innovation

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Reg impact assessment next in GenAI’s sights, experts claim

The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption

Improving life science R&D outcomes with AI

The medical device sector’s surging regulatory burden: how are suppliers coping?

Clinical

Tvardi Therapeutics Reports Phase 2 Failure for IPF Drug Candidate TTI-101

Editor Picks

Ivonescimab Shows 26% Reduction in Death Risk for EGFR-Mutated NSCLC Patients in Phase 3 Trial

Karuna Therapeutics Phase 1b Trial Results Reinforce Cardiovascular Safety of Schizophrenia Treatment KarXT

AbbVie Licenses Ex-China Rights to RemeGen’s PD-1/VEGF Bispecific RC148 for $650 Million Upfront

Must Read

Evommune Reports Phase 2a EVO301 Data in Moderate to Severe Atopic Dermatitis

FDA Rejects REGENXBIO’s RGX-121 Gene Therapy for Hunter Syndrome, Requests New Study

Eli Lilly Discontinues Three Clinical-Stage Programs Including Prevail Gene Therapy

Hot Topics

About Us

Follow Us